Please assess the completion status of the following clinical trial:

Trial Title: Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Past prior screening mammography (SM) interpreted as negative or benign (This screening must have been performed at Mayo Clinic Rochester, Minnesota).~2. Past prior SM interpreted as heterogeneously dense or extremely dense (This screening must have been performed at Mayo Clinic Rochester, Minnesota).~3. Women younger than 50 years who had not undergone prior mammography, as most of these women have dense breasts.~4. Subjects had to have at least one of the following risk factors:~   1. Known mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2)~  2. History of chest, mediastinal, or axillary irradiation~  3. Personal history of breast cancer~  4. History of prior biopsy showing atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or atypical papilloma~  5. Gail or Claus model lifetime risk greater than or equal to 20%~  6. Gail model 5 year risk greater or equal to 2.5%~  7. Gail model 5 year risk greater or equal to 1.6%~  8. One first-degree relative with history of breast cancer~  9. Two second-degree relatives with history of breast cancer~Exclusion Criteria:~1. They are unable to understand and sign the consent form~2. They are pregnant or lactating~3. They are physically unable to sit upright and still for 40 minutes.~4. They have self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass etc.).~5. They have had needle biopsy within 3 months, or breast surgery within 1 year prior to the study.~6. They are currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mammography and Molecular Breast Imaging (Type: EXPERIMENTAL): Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).